Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
COLGATE PALMOLIVE CO executive Malcolm Gregory reported an open-market sale of 2,300 shares of Common Stock at $88.44 per share. The sale was a direct transaction and left him with 13,598 shares held directly. He also has 8,599 shares held indirectly through the issuer's 401(k) Plan trustee.
COLGATE PALMOLIVE CO director Brian Newman reported routine equity awards. He received an annual director stock grant of 2,075 shares of common stock, bringing his direct holdings to 7,621 shares. These shares were granted under the company’s incentive compensation plan.
Newman was also granted stock options for 2,424 shares at an exercise price of $86.7400 per share, expiring on May 11, 2034. The options become exercisable in equal annual installments over three years starting on the first anniversary of the May 11, 2026 grant date. In addition, 36 shares are held indirectly through a family trust.
COLGATE PALMOLIVE CO director Kimberly A. Nelson received new equity compensation awards. On May 11, 2026, she acquired 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing her direct holdings to 11,634 shares.
On the same date, she also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. This option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the grant date. The filing also lists additional indirect holdings through a trust, spouse, and a family trust.
Colgate-Palmolive director Martina Hundmejean received equity awards as part of her annual compensation. She was granted 2,075 shares of Common Stock at no cost, credited to a stock unit account under the company’s incentive compensation plan, bringing her direct holdings to 16,206 shares.
She also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share. The option vests in equal annual installments over three years, starting on the first anniversary of the May 11, 2026 grant date. These are compensation-related grants, not open-market purchases or sales.
Colgate-Palmolive director Lorrie M. Norrington reported compensation-related equity awards. She received an annual director stock grant of 2,075 shares of common stock credited to a stock unit account under the company’s incentive compensation plan, bringing her direct common stock holdings to 42,312 shares.
She was also granted a stock option covering 2,424 shares of common stock at an exercise price of $86.74 per share. This option expires on May 11, 2034 and becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date.
Colgate-Palmolive director Harris C. Martin received new equity awards. On May 11, 2026, he was granted 1,556 shares of Common Stock as an annual director stock grant under the company’s incentive compensation plan.
He was also granted stock options for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. These options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. Following the stock grant, he directly holds 24,517 common shares, plus the newly granted options.
Colgate-Palmolive director Lisa Edwards received routine equity awards as part of her compensation. She was granted 2,075 shares of common stock and 2,424 stock options on May 11, 2026 under the company’s incentive compensation plan. After the grant, she directly owns 18,182 common shares.
The options allow her to buy 2,424 common shares at an exercise price of $86.74 per share and expire on May 11, 2034. They become exercisable in equal annual installments over three years, starting on the first anniversary of the grant date.
COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards. On May 11, 2026, he received an annual director stock grant of 2,075 shares of common stock, increasing his directly held shares to 28,216.
He also received an annual director stock option grant for 2,424 shares of common stock at a conversion price of $86.74 per share, with options vesting in equal annual installments over three years beginning on the first anniversary of the grant date and expiring on May 11, 2034. Separately, 36,357 shares are reported as held indirectly through a trust, which includes 2,019 shares previously reported as directly owned.
Colgate-Palmolive director Christopher S. Boerner reported equity compensation awards. He received an annual director stock grant of 1,383 shares of common stock under the company’s incentive compensation plan, leaving him with 1,383 common shares directly owned after the award.
He was also granted a stock option for 2,020 shares of common stock with an exercise price of $86.74 per share, expiring on May 11, 2034. The option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date. These are compensation-related awards rather than open-market purchases or sales.
COLGATE PALMOLIVE CO director John P. Bilbrey reported routine equity compensation and updated holdings. He received a grant of 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing his direct holdings to 39,820 shares. He also received an annual director stock option grant for 2,424 shares at an exercise price of $86.74 per share, expiring on May 11, 2034, which becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date. In addition, a separate entry reflects 4,719 shares of Common Stock held indirectly by a trust.